Dr. Peter Zang Receives Prestigious Award
Dr. Peter Zang has been awarded the highly esteemed Cary Presant, MD Young Investigator Award for his remarkable research on metastatic castrate-resistant prostate cancer (mCRPC), which is vital for improving treatment strategies and enhancing patient outcomes.
About the Cary Presant Award
This award, presented by the Medical Oncology Association of Southern California (MOASC), recognizes promising early-career researchers who have made significant contributions to oncology. The honor pays tribute to Dr. Cary Presant, who has significantly transformed the field through his groundbreaking work.
Dr. Zang's Research Focus
Dr. Zang has dedicated his career to addressing the challenges posed by mCRPC. This advanced stage of prostate cancer is complex and one of the leading causes of cancer mortality among men globally. His innovative research aims to uncover new treatment avenues that could potentially change clinical practices and improve survival rates.
Importance of Supporting Early-Career Researchers
According to Dr. Ashkan Lashkari, President of MOASC, Dr. Zang's commitment to advancing understanding in this challenging field represents the kind of dedication that significantly impacts the lives of many patients. As stated, "We are thrilled to honor Dr. Zang with the 2025 Cary Presant, MD Young Investigator Award; his dedication to advancing our understanding of metastatic prostate cancer is exemplary. His research holds the potential to improve outcomes significantly for patients battling this devastating disease."
Annual Celebration of Innovation in Oncology
The Cary Presant, MD Young Investigator Award highlights MOASC's ongoing commitment to nurturing talent in oncology research. As emphasized by Dr. Sumanta Pal, Vice President of MOASC, supporting promising researchers is crucial not just for the present, but for the future of the field. This initiative is made possible through AVEO Oncology’s generous support, emphasizing the importance of investing in new ideas and advancements that can lead to better patient care.
AVEO Oncology's Contribution
AVEO Oncology plays a significant role in sponsoring this award. As an oncology-focused biopharmaceutical company, AVEO is committed to developing treatments that offer patients better quality of life through innovative solutions. Their support exemplifies the collaboration necessary to drive advancements in the field of oncology.
MOASC’s Commitment to Excellence
MOASC is devoted to enhancing the practice of oncology by providing essential resources and advocacy for hematologists and oncologists. Representing over 650 members and multiple comprehensive cancer centers, MOASC's initiatives facilitate the growth of knowledge and research exchange in oncology, benefiting the entire medical community and, ultimately, patients.
Contact Information
For further inquiries, you can reach out to Nichole East, CAE, Executive Director at 909-985-9061, ext. 1002.
Frequently Asked Questions
What is the Cary Presant, MD Young Investigator Award?
This award is given annually to an early-career researcher who has shown extraordinary potential in the field of oncology.
Who is Dr. Peter Zang?
Dr. Peter Zang is a Fellow in Hematology and Medical Oncology at the City of Hope National Medical Center, recognized for his exceptional research in metastatic prostate cancer.
Why is Dr. Zang's research important?
His research addresses metastatic castrate-resistant prostate cancer, aiming to enhance treatment strategies and improve patient outcomes.
Who presents the Cary Presant Award?
The Medical Oncology Association of Southern California (MOASC) presents this prestigious award.
How does AVEO Oncology contribute to oncology research?
AVEO Oncology sponsors the Young Investigator Award, supporting innovative research to improve patient care and treatment strategies in oncology.
